Results 41 to 50 of about 349,757 (388)
Toward Homogenous Antibody Drug Conjugates Using Enzyme-Based Conjugation Approaches
Pharmaceuticals, 2021 In the last few decades, antibody-based diagnostic and therapeutic applications have been well established in medicine and have revolutionized cancer managements by improving tumor detection and treatment.
Ahmad Fawzi Hussain +8 more
doaj +1 more source
In Vivo Fluorescence Imaging of E-Selectin: Quantitative Detection of Endothelial Activation in Arthritis [PDF]
, 2010 Rheumatoid arthritis (RA) is a chronic progressive systemic inflammatory disease, characterized by synovial inflammation and localized destruction of cartilage and bone.
Gompels, Luke, Gompels, Luke
core +1 more source
Introduction to Antibody-Drug Conjugates [PDF]
Antibodies, 2021 Antibody-drug conjugates (ADCs) are innovative biopharmaceutical products in which a monoclonal antibody is linked to a small molecule drug with a stable linker. Most of the ADCs developed so far are for treating cancer, but there is enormous potential for using ADCs to treat other diseases.
openaire +3 more sources
Antibody–Drug Conjugates for Cancer Therapy [PDF]
Molecules, 2020 Antibody–drug conjugates (ADCs) are novel drugs that exploit the specificity of a monoclonal antibody (mAb) to reach target antigens expressed on cancer cells for the delivery of a potent cytotoxic payload. ADCs provide a unique opportunity to deliver drugs to tumor cells while minimizing toxicity to normal tissue, achieving wider therapeutic windows ...
Umbreen Hafeez +3 more
openaire +4 more sources
Xenobiotica; the fate of foreign compounds in biological systems, 2020 Trastuzumab deruxtecan (T-DXd, DS-8201a) is an antibody-drug conjugate (ADC), comprising an anti-HER2 antibody (Ab) at a drug-to-Ab ratio of 7–8 with the topoisomerase I inhibitor DXd.
Hiromi Okamoto +6 more
semanticscholar +1 more source
Potential novel therapy targets in neuroendocrine carcinomas of the breast [PDF]
, 2018 Neuroendocrine carcinoma (NEC) of the breast is a rare, special type of breast cancer, reportedly constituting 2% to 5% of all breast cancers. Although breast NEC does not have a specific targeted therapy, several new targeted therapies based on specific
Contreras, Elma +7 more
core +2 more sources
An Immunosuppressive Antibody–Drug Conjugate [PDF]
Journal of the American Chemical Society, 2015 We have developed a novel antibody-drug conjugate (ADC) that can selectively deliver the Lck inhibitor dasatinib to human T lymphocytes. This ADC is based on a humanized antibody that selectively binds with high affinity to CXCR4, an antigen that is selectively expressed on hematopoietic cells.
Wang, Rongsheng E +13 more
openaire +4 more sources
Chemical and pharmaceutical bulletin, 2019 A major limitation of traditional chemotherapy for cancer is dose-limiting toxicity, caused by the exposure of non-tumor cells to cytotoxic agents.
T. Nakada +4 more
semanticscholar +1 more source
Advances in Antibody–Drug Conjugate Design: Current Clinical Landscape and Future Innovations
SLAS discovery : advancing life sciences R & D, 2020 The targeted delivery of potent cytotoxic molecules into cancer cells is considered a promising anticancer strategy. The design of clinically effective antibody–drug conjugates (ADCs), in which biologically active drugs are coupled through chemical ...
Laurence Gauzy-Lazo +2 more
semanticscholar +1 more source
Non-internalising antibody–drug conjugates
Chemical Society Reviews, 2022 This review introduces non-internalising Antibody–Drug Conjugates (ADCs), highlighting the linker chemistry that enables extracellular payload release.
Nicola Ashman +2 more
openaire +2 more sources